Klaricid (clarithromycin): Reviews and patient testimonials

/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1564492295

Medication indications

Klaricid Adult Sachet 250 mg

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Klaricid Adult Sachets 250mg are indicated in adults and children 12 years and older.

Clarithromycin is indicated in the treatment of infections caused by one or more susceptible organisms. Indications include:

Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia (see section 4.4 and 5.1 regarding Sensitivity Testing).

Upper respiratory tract infections for example, sinusitus and pharyngitis.

Clarithromycin is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section.

Clarithromycin is also indicated in skin and soft tissue infections of mild to moderate severity (e.g. folliculitis, cellulitis, erysipelas) (see section 4.4 and 5.1 regarding Sensitivity Testing).

Clarithromycin in the presence of acid suppression effected by lansoprazole or omeprazole is also indicated for the eradication of H. pylori in patients with duodenal ulcers. See Dosage and Administration section.

Clarithromycin is usually active against the following organisms in vitro:

Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible); Streptococcus pyogenes (Group A beta-haemolytic streptococci); alpha-haemolytic streptococci (viridans group); Streptococcus (Diplococcus) pneumoniae; Streptococcus agalactiae; Listeria monocytogenes.

Gram-negative Bacteria: Haemophilus influenzae; Haemophilus parainfluenzae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; Legionella pneumophila; Bordetella pertussis; Helicobacter pylori; Campylobacter jejuni.

Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.

Other Organisms: Chlamydia trachomatis; Mycobacterium avium; Mycobacterium leprae.

Anaerobes: Macrolide-susceptible Bacteroides fragilis; Clostridium perfringens; Peptococcus species; Peptostreptococcus species; Propionibacterium acnes.

Clarithromycin has bactericidal activity against several bacterial strains. These organisms include Haemophilus influenzae; Streptococcus pneumoniae; Streptococcus pyogenes; Streptococcus agalactiae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; Helicobacter pylori and Campylobacter spp.

The activity of clarithromycin against H. pylori is greater at neutral pH than at acid pH.

Klaricid Paediatric Suspension 125mg/5ml

Klaricid Paediatric Suspension 125mg/5ml is indicated in children 6 months to 12 years.

Klaricid Paediatric Suspension 125mg/5ml is indicated for the treatment of infections caused by susceptible organisms. Indications include:

- Lower respiratory tract infections (e.g. bronchitis, pneumonia) (see section 4.4 and 5.1 regarding Sensitivity Testing).

- Upper respiratory tract infections (e.g. pharyngitis, sinusitis).

- Skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas) (see section 4.4 and 5.1 regarding Sensitivity Testing).

- Acute otitis media.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Klaricid Paediatric Suspension 250mg/5ml

Klaricid Paediatric Suspension 250mg/5ml is indicated in children 6 months to 12 years.

Klaricid Paediatric Suspension 250mg/5ml is indicated for the treatment of infections caused by susceptible organisms. Indications include:

- Lower respiratory tract infections (e.g. bronchitis, pneumonia) (see section 4.4 and 5.1 regarding Sensitivity Testing).

- Upper respiratory tract infections (e.g. pharyngitis, sinusitis).

- Skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas) (see section 4.4 and 5.1 regarding Sensitivity Testing).

- Acute otitis media.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Klaricid XL 500mg tablets

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Klaricid XL 500 mg Tablets are indicated in adults and children 12 years and older.

Klaricid XL 500 mg Tablets are indicated for treatment of infections caused by susceptible organisms. Indications include:

Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia (see section 4.4 and 5.1 regarding Sensitivity Testing).

Upper respiratory tract infections for example, sinusitis and pharyngitis.

Klaricid XL 500 mg Tablets are also indicated in skin and soft tissue infections of mild to moderate severity, for example folliculitis, cellulitis and erysipelas (see section 4.4 and 5.1 regarding Sensitivity Testing).


Route of administration: Oral
Molecule: clarithromycin

Patients' opinions on Klaricid

In brief

General satisfaction level: Be the first to evaluate

Treatment's effectiveness: Be the first to evaluate

Ease of use: Be the first to evaluate

Adherence to prescription: Be the first to evaluate

Detected side effects: Be the first to evaluate

Improvement in the quality of life: Be the first to evaluate

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.